A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma
Annals of Surgery - United States
doi 10.1097/sla.0000000000000251
Full Text
Open PDFAbstract
Available in full text
Categories
Date
July 1, 2014
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)